CC
GOSS icon

Callan Capital’s Gossamer Bio GOSS Stock Holding History

Callan Capital’s Portfolio GOSS Stock Details GOSS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$31.5K Buy
30,000
+10,000
+50% +$11.6K ﹤0.01% 364
2024
Q4 		$13K Buy
+20,000
New +$17.1K ﹤0.01% 345

Other funds holding GOSS

OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Callan Capital's GOSS Position: Q1 2025 in Review

Callan Capital sold out of Gossamer Bio (GOSS) in Q1 2025, closing a stake of 30,000 shares — an estimated $34.7K sold.

Callan Capital first reported a position in GOSS in Q4 2024 and held it in 1 quarter. The position peaked at $27.1K in Q4 2024. 118 funds tracked by Wall St. Rank hold GOSS as of Q1 2025.

  • Callan Capital reported no remaining Gossamer Bio position as of Q1 2025 after selling out during the quarter.
  • Callan Capital sold 30,000 Gossamer Bio shares in Q1 2025, an estimated $34.7K.
  • Callan Capital first reported a position in Gossamer Bio in Q4 2024 and held it in 1 quarter.
  • Callan Capital's Gossamer Bio position peaked at $27.1K in Q4 2024.
  • 118 funds tracked by Wall St. Rank held Gossamer Bio as of Q1 2025.

Based on Callan Capital's 13F filing for Q1 2025, filed 29 Apr 2025.